A phase Ia/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed/refractory CLL, DLBCL or other B-cell lymphomas Meeting Abstract

  

Authors:	Mato, A. R.; Schuster, S. J.; Foss, F. M.; Isufi, I.; Ding, W.; Brander, D. M.; Sitlinger, A.; Tun, H. W.; Moustafa, M. A.; Kennard, K.; King, C. M.; Koehler, A.; Aitken, C.; He, W.; Kearney, A.; Gui, M.; Anderson, B. D.; Rosenthal, A. C.; Roeker, L. E.; Huntington, S. F.
Abstract Title:	A phase Ia/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed/refractory CLL, DLBCL or other B-cell lymphomas
Meeting Title:	61st Annual Meeting and Exposition of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	134
Issue:	Suppl. 1
Meeting Dates:	2019 Dec 7-10
Meeting Location:	Orlando, FL
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2019-11-13
Language:	English
ACCESSION:	WOS:000518218500873
DOI:	10.1182/blood-2019-126192
PROVIDER:	wos
Notes:	Meeting Abstract: 810 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/171869